Oncternal Therapeutics Inc

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Oncternal Therapeutics Inc reports Q1 loss but advances promising therapies

Oncternal Therapeutics Inc's Q1 2024 performance reflects ongoing investment in innovative therapies amidst a net loss of $8.4 million.
The company's financial stability, upcoming milestones, and engagement with analysts position it well for future growth and development.
Challenges in managing expenses, meeting clinical data timelines, and ensuring therapeutic success underscore the need for strategic decision-making and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Jim Breitmeyer - President and Chief Executive Officer Salim Yazji - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Kemp Dolliver - Brookline Capital Markets Operator Greetings and welcome to the Oncternal Therapeutics Second Quarter 2024 Financial Results Call. [Operator Instructions] As a reminder, this conference is being recorded.

Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript

Oncternal Therapeutics (ONCT) came out with a quarterly loss of $2.89 per share versus the Zacks Consensus Estimate of a loss of $3.03. This compares to loss of $3 per share a year ago.

Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported second quarter 2024 financial results.

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2024 financial results after the U.S. financial markets close on Thursday, August 8, 2024. Oncternal's management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company's financial results.

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results

SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal's President and Chief Executive Officer will present at the JonesTrading Healthcare Seaside Summit being held July 14-16, 2024 in San Diego, California.

Oncternal Therapeutics to Present in JonesTrading Healthcare Summit

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the fifth dose cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients with metastatic castration-resistant prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). Patients in the fifth cohort are receiving ONCT-534, the company's dual-action androgen receptor inhibitor (DAARI), at a dose of 600 mg taken orally once each day. The decision to proceed to this higher dose level was made by the study's Safety Review Committee (SRC) after reviewing data from the fourth dose level of 300 mg ONCT-534 daily. An initial update on ONCT-534 safety and efficacy based on prostate-specific antigen (PSA) levels from this study is expected in the third quarter of 2024 and will include data from this 600 mg dose cohort.

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q1 2024 Earnings Call Transcript May 9, 2024 5:00 PM ET Company Participants Richard Vincent - CFO Dr. James Breitmeyer - President and CEO Dr. Salim Yazji - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Hartaj Singh - Oppenheimer Robert Burns - HC Wainwright Kemp Dolliver - Brookline Capital Markets Operator Greetings, welcome to Oncternal's First Quarter 2024 Financial Results Call. At this time, all participants are in a listen-only mode.

Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call Transcript

Oncternal Therapeutics (ONCT) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $2.88. This compares to loss of $4 per share a year ago.

Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported first quarter 2024 financial results.

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

Oncternal Therapeutics (ONCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Oncternal Therapeutics (ONCT) Rating Upgrade to Buy

SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2024 financial results after the U.S. financial markets close on Thursday, May 9, 2024. Oncternal's management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company's financial results.

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results

SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Anne C. Hansen, who is joining Oncternal as Senior Director, Clinical Data Management.

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Oncternal Therapeutics (ONCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Oncternal Therapeutics (ONCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the fourth cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). Patients in the fourth dosing cohort will receive ONCT-534, the company's dual-action androgen receptor inhibitor (DAARI), at a dose of 300 mg taken orally each day. The decision to proceed to this higher dose level was made by the study's Safety Review Committee (SRC) after reviewing data from the patients treated to date, including the third dose level of 160 mg ONCT-534 daily.

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the Treatment Landscape & New Treatment Options for Prostate Cancer.

Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q4 2023 Results Conference Call March 7, 2024 5:00 PM ET Company Participants Richard Vincent - CFO Dr. James Breitmeyer - President and CEO Dr. Salim Yazji - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Hartaj Singh - Oppenheimer Kemp Dolliver - Brookline Capital Markets Operator Greetings, and welcome to Oncternal's Fourth Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.

Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call Transcript

Oncternal Therapeutics (ONCT) came out with a quarterly loss of $3.11 per share versus the Zacks Consensus Estimate of a loss of $3.09. This compares to loss of $4 per share a year ago.

Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates

SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2023 financial results.

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2023 financial results after the U.S. financial markets close on Thursday, March 7, 2024. Oncternal's management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company's financial results.

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal's President and Chief Executive Officer will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.

Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the fourth patient has now been enrolled into its Phase 1/2 study of ONCT-534, its dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). The last two patients were enrolled into the third dosing cohort, to receive ONCT-534 at a dose of 160 mg taken orally each day. The study utilizes an adaptive Bayesian Optimal Interval (BOIN) design, under which the first two dosing cohorts treated one patient each at 40 mg ONCT-534 per day and 80 mg ONCT-534 per day, respectively. The decision to proceed to dose level 3 was confirmed by the study's Safety Review Committee (SRC).

Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that its board of directors (Board) has approved a 1-for-20 reverse stock split of the company's common stock. The reverse stock split will become effective at 12:01 a.m. Eastern time on January 8, 2024. The company's common stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market under the same symbol (ONCT) when the market opens on January 8, 2024 with the new CUSIP number 68236P206.

Oncternal Therapeutics Announces Reverse Stock Split

SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today updated the status of its dose escalation/dose expansion Phase 1/2 Study ONCT-808-101, evaluating the company's ROR1-targeting autologous CAR T cell therapy ONCT-808 for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment.

Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Richard Vincent - CFO James Breitmeyer - President and CEO Salim Yazji - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Securities Hartaj Singh - Oppenheimer Kemp Dolliver - Brookline Capital Markets Operator Greetings and welcome to Oncternal Therapeutics third-quarter 2023 financial results conference call. [Operator Instructions].

Oncternal Therapeutics, Inc. (ONCT) Q3 2023 Earnings Call Transcript

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported third quarter 2023 financial results.

News for Oncternal Therapeutics Inc Stock (ONCT)